MetaVia is trading at $1.26, down -5.94%, with no verified company-specific announcement explaining the after-hours decline.
- MetaVia had announced a presentation of Phase 1 DA-1726 data at the Precision Liver Symposium on November 4; that event does not establish a reason for the move.
- Broader market signals were mixed, so the decline cannot be confidently attributed to market sentiment.